Subject:
- Active Substance: Siponimod
- Name: N.N.
- Therapeutic area: Secondary Progressive Multiple Sclerosis (SPMS)
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Publication of project plan: 20.11.2019
- Publication of final assessment expected: 13.02.2020
Assessment information:
- Title: Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS)
- Author/Co-Author: INFARMED (Portugal), NCPE (Ireland)
- Dedicated Reviewers: AIFA (Italy), ZIN (Netherlands), SESCS/FUNCANIS (Spain), RER (Italy)
› G-BA assessment available (D-513)